NFE2L2 and supranuclear palsy, progressive, 1: In vivo and in vitro experiments showed that the reduction in Nrf2 and NQO1, which are anti-oxidative stress-related proteins, although induced by MPTP, was restored after PSP administration, which indicated the anti-dopaminergic neurodegeneration ability of PSP [118].